EGFR and non-small cell lung carcinoma: However, at the same time, the large phase III study BR21 (119) demonstrated that erlotinib extends survival and alleviates symptoms in previously treated NSCLC patients compared to placebo, which further confirmed the status of EGFR-TKI.